GlaxoSmithKline Pakistan Limited reported a revenue of Rs 31.52 billion for the half year ended June 30, 2026
Filed as: Financial Results for the Quarter Ended June 30, 2026
Summary
GlaxoSmithKline Pakistan Limited reported a revenue of Rs 31.52 billion for the half year ended June 30, 2026, with a net profit of Rs 4.58 billion. The company declared an interim cash dividend of Rs 7.0 per share.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 31.52B | PKR 30.30B | +4.0% |
| Net Profit | PKR 4.58B | PKR 4.20B | +9.2% |
| Earnings Per Share | PKR 14.38 | PKR 13.17 | +9.2% |
| Operating Profit | PKR 7.96B | PKR 7.23B | +10.0% |
| Cash Dividend Per Share | PKR 7.0 | — | — |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased to Rs 31.52 billion from Rs 30.30 billion, a growth of 4.02%.
- Net profit rose to Rs 4.58 billion from Rs 4.20 billion, marking a 9.17% increase.
- Earnings per share slightly decreased to Rs 14.38 from Rs 13.17, reflecting a 9.18% increase.
GlaxoSmithKline Pakistan Limited (GLAXO) on Nafa
Last price Rs 336.89 · Pharmaceuticals · You can own GLAXO shares from your phone.
More GLAXO announcements
- NoticeTransmission of Quarterly Report for the Period Ended September 30, 2026
- Financial resultGlaxoSmithKline Pakistan Limited reported a revenue of Rs 48.11 billion for the nine months ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30, 2026
- NoticeBoard Meeting Quarter 3-2026
- NoticeShariah Disclosure for the Half Year ended June 30, 2026
- NoticeCredit of Interim Cash Dividend
- NoticeAppointment of Chief Financial Officer
Source: GlaxoSmithKline Pakistan Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.